Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 156719, 11 pages
http://dx.doi.org/10.1155/2015/156719
Review Article

Helicobacter pylori Antibody Titer and Gastric Cancer Screening

Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan

Received 14 June 2015; Accepted 6 September 2015

Academic Editor: Hamid Raziee

Copyright © 2015 Hiroshi Kishikawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Miki, “Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—‘ABC method’,” Proceedings of the Japan Academy Series B: Physical and Biological Sciences, vol. 87, no. 7, pp. 405–414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Watabe, T. Mitsushima, Y. Yamaji et al., “Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study,” Gut, vol. 54, no. 6, pp. 764–768, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Kudo, S. Kakizaki, N. Sohara et al., “Analysis of ABC (D) stratification for screening patients with gastric cancer,” World Journal of Gastroenterology, vol. 17, no. 43, pp. 4793–4798, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Mizuno, I. Miki, T. Ishida et al., “Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis,” Digestive Diseases and Sciences, vol. 55, no. 11, pp. 3132–3137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Tatemichi, S. Sasazuki, M. Inoue, and S. Tsugane, “Clinical significance of IgG antibody titer against Helicobacter pylori,” Helicobacter, vol. 14, no. 3, pp. 231–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Suzuki, H. Cullings, S. Fujiwara et al., “Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori,” Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 6, pp. 1224–1228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Watanabe, J. Kato, I. Inoue et al., “Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis,” International Journal of Cancer, vol. 131, no. 11, pp. 2632–2642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Yoshida, J. Kato, I. Inoue et al., “Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer,” International Journal of Cancer, vol. 134, no. 6, pp. 1445–1457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Tonkic, M. Tonkic, P. Lehours, and F. Mégraud, “Epidemiology and diagnosis of Helicobacter pylori infection,” Helicobacter, vol. 17, supplement 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kodama, K. Murakami, T. Okimoto et al., “Infuence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test,” World Journal of Gastroenterology, vol. 18, no. 1, pp. 44–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Parente, M. Sainaghi, O. Sangaletti et al., “Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 3, pp. 553–557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Bradley, N. Motterlini, S. Padmanabhan et al., “Potentially inappropriate prescribing among older people in the United Kingdom,” BMC Geriatrics, vol. 14, article 72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Covacci, S. Censini, M. Bugnoli et al., “Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 12, pp. 5791–5795, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Blaser, G. I. Perez-Perez, H. Kleanthous et al., “Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach,” Cancer Research, vol. 55, no. 10, pp. 2111–2115, 1995. View at Google Scholar · View at Scopus
  16. J. Q. Huang, G. F. Zheng, K. Sumanac, E. J. Irvine, and R. H. Hunt, “Meta-analysis of the relationship between cagA seropositivity and gastric cancer,” Gastroenterology, vol. 125, no. 6, pp. 1636–1644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Shimoyama, S. Fukuda, M. Tanaka, T. Mikami, Y. Saito, and A. Munakata, “High prevalence of the CagA-positive Helicobacter pylori strains in Japanese asymptomatic patients and gastric cancer patients,” Scandinavian Journal of Gastroenterology, vol. 32, no. 5, pp. 465–468, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Censini, C. Lange, Z. Xiang et al., “Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14648–14653, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sasazuki, M. Inoue, M. Iwasaki et al., “Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 7, pp. 1341–1347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. V. V. Tsukanov, N. N. Butorin, A. S. Maady et al., “Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in eastern Siberia,” Helicobacter, vol. 16, no. 2, pp. 107–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Burucoa, J.-C. Delchier, A. Courillon-Mallet et al., “Comparative evaluation of 29 commercial Helicobacter pylori serological kits,” Helicobacter, vol. 18, no. 3, pp. 169–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. T. T. H. Hoang, T.-U. Wheeldon, C. Bengtsson, D. C. Phung, M. Sörberg, and M. Granström, “Enzyme-linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated,” Journal of Clinical Microbiology, vol. 42, no. 2, pp. 627–630, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Bergey, P. Marchildon, J. Peacock, and F. Mégraud, “What is the role of serology in assessing Helicobacter pylori eradication,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 6, pp. 635–639, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. L. H. Eusebi, R. M. Zagari, and F. Bazzoli, “Epidemiology of Helicobacter pylori Infection,” Helicobacter, vol. 19, supplement 1, pp. 1–5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Xie and N.-H. Lu, “Review: clinical management of Helicobacter pylori infection in china,” Helicobacter, vol. 20, no. 1, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Shimoyama, M. Aoki, Y. Sasaki, M. Matsuzaka, S. Nakaji, and S. Fukuda, “ABC screening for gastric cancer is not applicable in a Japanese population with high prevalence of atrophic gastritis,” Gastric Cancer, vol. 15, no. 3, pp. 331–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. I. M. Samloff, “Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence,” Gastroenterology, vol. 61, no. 2, pp. 185–188, 1971. View at Google Scholar · View at Scopus
  28. I. M. Samloff and W. M. Liebman, “Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence,” Gastroenterology, vol. 65, no. 1, pp. 36–42, 1973. View at Google Scholar · View at Scopus
  29. K. Miki, M. Ichinose, C. Furihata et al., “Potential peptic activity of pepsinogen of human gastroduodenal mucosa determined by fluorescent microassay method using succinyl albumin,” Clinica Chimica Acta, vol. 121, no. 3, pp. 337–344, 1982. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Miki, M. Morita, M. Sasajima, R. Hoshina, E. Kanda, and Y. Urita, “Usefulness of gastric cancer screening using the serum pepsinogen test method,” The American Journal of Gastroenterology, vol. 98, no. 4, pp. 735–739, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Kitahara, K. Kobayashi, T. Sato, Y. Kojima, T. Araki, and M. A. Fujino, “Accuracy of screening for gastric cancer using serum pepsinogen concentrations,” Gut, vol. 44, no. 5, pp. 693–697, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Watanabe, J. H. Kurata, S. Mizuno et al., “Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan,” Digestive Diseases and Sciences, vol. 42, no. 7, pp. 1383–1387, 1997. View at Google Scholar
  33. M. Dinis-Ribeiro, M. Areia, A. C. de Vries et al., “Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED),” Endoscopy, vol. 44, no. 1, pp. 74–94, 2012. View at Publisher · View at Google Scholar
  34. Y. Yamaji, H. Watabe, H. Yoshida et al., “High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors,” Helicobacter, vol. 14, no. 2, pp. 81–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Yanaoka, M. Oka, C. Mukoubayashi et al., “Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 4, pp. 838–845, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Lomba-Viana, M. Dinis-Ribeiro, F. Fonseca, A. S. Vieira, M. J. B. Bento, and H. Lomba-Viana, “Serum pepsinogen test for early detection of gastric cancer in a European country,” European Journal of Gastroenterology and Hepatology, vol. 24, no. 1, pp. 37–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Yanaoka, M. Oka, N. Yoshimura et al., “Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels,” International Journal of Cancer, vol. 123, no. 4, pp. 917–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Eshmuratov, J. C. Nah, N. Kim et al., “The correlation of endoscopic and histological diagnosis of gastric atrophy,” Digestive Diseases and Sciences, vol. 55, no. 5, pp. 1364–1375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Redéen, F. Petersson, K.-A. Jönsson, and K. Borch, “Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample,” Endoscopy, vol. 35, no. 11, pp. 946–950, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Rubicz, C. T. Leach, E. Kraig et al., “Genetic factors influence serological measures of common infections,” Human Heredity, vol. 72, no. 2, pp. 133–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Wang, E. W. Y. Chang, S. C. Wong, S.-M. Ong, D. Q. Y. Chong, and K. L. Ling, “Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins,” The Journal of Immunology, vol. 190, no. 2, pp. 794–804, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Kreuning, J. Lindeman, I. Biemond, and C. B. Lamer, “Relation between IgG and IgA antibody titres against Helicobacter pylori in serum and severity of gastritis in asymptomatic subjects,” Journal of Clinical Pathology, vol. 47, no. 3, pp. 227–231, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. R. M. Zagari, P. Pozzato, C. Martuzzi et al., “13C-urea breath test to assess Helicobacter pylori bacterial load,” Helicobacter, vol. 10, no. 6, pp. 615–619, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Koizumi, S. Tanabe, H. Imaizumi et al., “Effect of anti-Helicobacter pylori IgG antibody titer following eradication of Helicobacter pylori infection,” Hepato-Gastroenterology, vol. 50, no. 49, pp. 293–296, 2003. View at Google Scholar · View at Scopus
  45. P. Marchildon, D. H. Balaban, M. Sue et al., “Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 94, no. 8, pp. 2105–2108, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Correa, “Human gastric carcinogenesis: a multistep and multifactorial process—first American cancer society award lecture on cancer epidemiology and prevention,” Cancer Research, vol. 52, no. 24, pp. 6735–6740, 1992. View at Google Scholar · View at Scopus
  47. K. Kimura, “Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach,” Gastroenterology, vol. 63, no. 4, pp. 584–592, 1972. View at Google Scholar · View at Scopus
  48. D. Forman, D. G. Newell, F. Fullerton et al., “Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation,” British Medical Journal, vol. 302, no. 6788, pp. 1302–1305, 1991. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Nomura, G. N. Stemmermann, P.-H. Chyou, I. Kato, G. I. Perez-Perez, and M. J. Blaser, “Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii,” The New England Journal of Medicine, vol. 325, no. 16, pp. 1132–1136, 1991. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Fujioka, M. T. Fahey, G. S. Hamada et al., “Serological immunoglobulin G antibody titers to Helicobacter pylori in Japanese Brazilian and non-Japanese Brazilian gastric cancer patients and controls in São Paul,” Japanese Journal of Cancer Research, vol. 92, no. 8, pp. 829–835, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Yamaji, T. Mitsushima, H. Ikuma et al., “Weak response of Helicobacter pylori antibody is high risk for gastric cancer: a cross-sectional study of 10,234 endoscoped Japanese,” Scandinavian Journal of Gastroenterology, vol. 37, no. 2, pp. 148–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. W. E. Karnes Jr., I. M. Samloff, M. Siurala et al., “Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis,” Gastroenterology, vol. 101, no. 1, pp. 167–174, 1991. View at Google Scholar · View at Scopus
  53. A. Kokkola, T. U. Kosunen, P. Puolakkainen et al., “Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis,” APMIS, vol. 111, no. 6, pp. 619–624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Kishikawa, J. Nishida, H. Ichikawa et al., “Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status,” Helicobacter, vol. 16, no. 6, pp. 427–433, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Ohata, S. Kitauchi, N. Yoshimura et al., “Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer,” International Journal of Cancer, vol. 109, no. 1, pp. 138–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. D. J. Morgan, I. N. Okeke, R. Laxminarayan, E. N. Perencevich, and S. Weisenberg, “Non-prescription antimicrobial use worldwide: a systematic review,” The Lancet Infectious Diseases, vol. 11, no. 9, pp. 692–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. F. W. Arnold, L. C. McDonald, R. S. Smith, D. Newman, and J. A. Ramirez, “Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians,” Infection Control and Hospital Epidemiology, vol. 27, no. 4, pp. 378–382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. G. H. Kawanami and C. M. Fortaleza, “Factors predictive of inappropriateness in requests for parenteral antimicrobials for therapeutic purposes: a study in a small teaching hospital in Brazil,” Scandinavian Journal of Infectious Diseases, vol. 43, no. 6-7, pp. 528–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Imai-Kamata and K. Fushimi, “Factors associated with adherence to prophylactic antibiotic therapy for elective general surgeries in Japan,” International Journal for Quality in Health Care, vol. 23, no. 2, pp. 167–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Shiota, R. Reddy, A. Alsarraj, H. B. El-Serag, and D. Y. Graham, “Antibiotic resistance of Helicobacter pylori among male US veterans,” Clinical Gastroenterology and Hepatology, vol. 11, no. 5, pp. 646–664, 2009. View at Google Scholar
  61. F. Giorgio, M. Principi, V. De Francesco et al., “Primary clarithromycin resistance to Helicobacter pylori: is this the main reason for triple therapy failure?” World Journal of Gastrointestinal Pathophysiology, vol. 4, no. 3, pp. 43–46, 2013. View at Publisher · View at Google Scholar
  62. V. De Francesco, M. Margiotta, A. Zullo et al., “Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 783–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Okamura, T. Suga, T. Nagaya et al., “Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison,” Helicobacter, vol. 19, no. 3, pp. 214–220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. J. K. Leyenaar, T. Lagu, M.-S. Shieh, P. S. Pekow, and P. K. Lindenauer, “Variation in resource utilization for the management of uncomplicated community-acquired pneumonia across community and children's hospitals,” Journal of Pediatrics, vol. 165, no. 3, pp. 585–591, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. J.-L. Ma, L. Zhang, L. M. Brown et al., “Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality,” Journal of the National Cancer Institute, vol. 104, no. 6, pp. 488–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Fukase, M. Kato, S. Kikuchi et al., “Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial,” The Lancet, vol. 372, no. 9636, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. A. C. Ford, D. Forman, R. H. Hunt, Y. Yuan, and P. Moayyedi, “Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials,” British Medical Journal, vol. 348, Article ID g3174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. L. Fuccio, R. M. Zagari, L. H. Eusebi et al., “Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?” Annals of Internal Medicine, vol. 151, no. 2, pp. 121–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. X. Zhang, L. Xue, L. Xing et al., “Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community,” International Journal of Cancer, vol. 130, no. 7, pp. 1614–1619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Boda, M. Ito, M. Yoshihara et al., “Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm,” Helicobacter, vol. 19, no. 1, pp. 1–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Ono, M. Kato, M. Suzuki et al., “Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy,” Digestion, vol. 86, no. 1, pp. 59–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Kato, N. Matsukura, K. Tsukada et al., “Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics,” Cancer Science, vol. 98, no. 6, pp. 790–794, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Kakinoki, R. Kushima, A. Matsubara et al., “Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases,” Digestive Diseases and Sciences, vol. 54, no. 3, pp. 614–620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. I. Pimanov, E. V. Makarenko, A. V. Voropaeva, M. E. Matveenko, and E. V. Voropaev, “Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer,” Journal of Gastroenterology and Hepatology, vol. 23, no. 11, pp. 1666–1671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. B. A. Salih, M. F. Abasiyanik, H. Saribasak, O. Huten, and E. Sander, “A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology,” Digestive Diseases and Sciences, vol. 50, no. 8, pp. 1517–1522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Wu, J. A. Rusiecki, K. Zhu, J. Potter, and S. S. Devesa, “Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 7, pp. 1945–1952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Hansen, S. E. Vollset, M. H. Derakhshan et al., “Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status,” Gut, vol. 56, no. 7, pp. 918–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Niwa, T. Tsukamoto, T. Toyoda et al., “Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells,” Cancer Research, vol. 70, no. 4, pp. 1430–1440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Shiota, K. Murakami, T. Okimoto, M. Kodama, and Y. Yamaoka, “Serum Helicobacter pylori CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan,” Journal of Gastroenterology and Hepatology, vol. 29, no. 1, pp. 67–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Tatemichi, S. Sasazuki, M. Inoue, and S. Tsugane, “Different etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study using IgG titer against Hp surface antigen,” Acta Oncologica, vol. 47, no. 3, pp. 360–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. B. C.-Y. Wong, S. K. Lam, W. M. Wong et al., “Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial,” The Journal of the American Medical Association, vol. 291, no. 2, pp. 187–194, 2004. View at Publisher · View at Google Scholar · View at Scopus